Furthermore, dabrafenib in combination with trametinib, a MEK inhibitor [21], demonstrated a higher response rate and improved clinical efficacy [45]; consequently, the FDA approved these two drugs as monotherapies as well as in combination for treating patients with BRAF-mutant metastatic melanoma [47]. Here, MAP2K7 is linked to metastatic melanoma.